Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:14:48 EST Fri 06 Feb 2026
Enter Symbol
or Name
USA
CA



Q:VCYT - VERACYTE INC - https://www.veracyte.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VCYT - Q3.034.00·43.650.136.19+1.333.81,203.442,57710,65235.67  36.50  34.7150.71  22.6117:18:21Feb 0415 min RT 2¢

Recent Trades - Last 10 of 10652
Time ETExPriceChangeVolume
17:18:21Q36.902.047
17:17:02Q37.002.14100
16:29:23Q35.490.632
16:20:00Q36.191.33446
16:10:05Q36.191.331
16:04:48Q36.191.331
16:04:47Q36.191.331
16:04:45Q36.191.331
16:04:33Q36.191.331
16:01:55Q36.191.33780

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-04 17:15U:VCYTNews ReleaseVeracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
2026-01-11 16:30U:VCYTNews ReleaseVeracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
2025-12-29 16:30U:VCYTNews ReleaseVeracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference
2025-11-06 08:30U:VCYTNews ReleaseVeracyte to Participate in Upcoming Investor Conferences
2025-11-04 16:05U:VCYTNews ReleaseVeracyte Announces Third Quarter 2025 Financial Results
2025-11-03 16:15U:VCYTNews ReleaseVeracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing
2025-10-15 17:31U:VCYTNews ReleaseVeracyte to Release Third Quarter 2025 Financial Results on November 4, 2025
2025-09-28 16:00U:VCYTNews ReleaseVeracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer
2025-09-24 09:00U:VCYTNews ReleaseVeracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025
2025-09-09 09:00U:VCYTNews ReleaseVeracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting
2025-08-29 08:30U:VCYTNews ReleaseVeracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
2025-08-27 11:25U:VCYTNews ReleaseVeracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
2025-08-26 08:30U:VCYTNews ReleaseVeracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test
2025-08-06 16:05U:VCYTNews ReleaseVeracyte Announces Second Quarter 2025 Financial Results
2025-07-24 17:58U:VCYTNews ReleaseVeracyte Set to Join S&P SmallCap 600
2025-07-17 17:30U:VCYTNews ReleaseVeracyte to Release Second Quarter 2025 Financial Results on August 6, 2025
2025-07-08 16:05U:VCYTNews ReleaseVeracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025
2025-05-28 16:05U:VCYTNews ReleaseVeracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research
2025-05-20 17:00U:VCYTNews ReleaseVeracyte to Participate in Upcoming Investor Conferences
2025-05-07 16:05U:VCYTNews ReleaseVeracyte Announces First Quarter 2025 Financial Results